Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Immunotherapy Clinical Trials

14 recruiting trials for Immunotherapy. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
14
Total Trials
14
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT07291921

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics,...

This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS),...

Sponsor: Peking University People's HospitalEnrolling: 1001 location
RECRUITINGPhase 1NCT03198546

GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been...

Sponsor: Second Affiliated Hospital of Guangzhou Medical UniversityEnrolling: 302 locations
RECRUITINGPhase 2NCT07198165

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

This study aims to evaluate the efficacy and safety of short-course radiotherapy combined with CAPOX plus bevacizumab with or without a PD-1 inhibitor in patients with locally...

Sponsor: Ruijin HospitalEnrolling: 1041 location
RECRUITINGNCT07327489

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies

This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a...

Sponsor: ElephasEnrolling: 20008 locations
RECRUITINGPhase 1NCT07260591

VSV-02 Compassionate Use in Advanced Solid Tumors

This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational...

Sponsor: The First Affiliated Hospital of Xinxiang Medical CollegeEnrolling: 61 location
RECRUITINGPhase 2NCT06702826

Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases

The goal of this clinical trial is to evaluate the efficacy and safety of Cadonilimab combined with stereotactic radiation therapy in the second-line treatment of brain metastases...

Sponsor: Rongrong ZhouEnrolling: 201 location
RECRUITINGPhase 4NCT06903312

Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

This is Phase IV, randomized, multi arm, multicenter, low interventional clinical trial, aiming to evaluate if treatment of primary tumor in mRCC patients with initial benefit to...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 4091 location
RECRUITINGPhase 2NCT07475403

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

This study aims to evaluate whether urinary tumor DNA (utDNA) can guide treatment duration in patients with unresectable very-high-risk non-muscle-invasive bladder cancer (VHR...

Sponsor: Tianjin Medical University Second HospitalEnrolling: 531 location
RECRUITINGNCT06915389

Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients

This study comprehensively examines metabolic and lipidomic dynamics in gastric cancer patients initiating PD-1/PD-L1 inhibitor therapy, employing a longitudinal design with pre-...

Sponsor: Qinghai Red Cross HospitalEnrolling: 1001 location
RECRUITINGPhase 2NCT07165847

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and...

Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial...

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityEnrolling: 401 location
RECRUITINGPhase 3NCT06964568

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous...

Sponsor: Fudan UniversityEnrolling: 4521 location
RECRUITINGNCT05967910

The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)

Chronic stress refers to a special emotional state caused by unexpected stress for a long time, with an increasing incidence in the population. It can cause the body to release...

Sponsor: Second Xiangya Hospital of Central South UniversityEnrolling: 2001 location
RECRUITINGPhase 2NCT06410651

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 531 location
RECRUITINGPhase 4NCT05493267

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the...

Sponsor: Shanghai Pulmonary Hospital, Shanghai, ChinaEnrolling: 302 locations